Haemonetics Corporation (HAE) Guidance & Earnings Results

On 2026-08-06 Haemonetics Corporation raised guidance: "FY27 organic revenue raised to 4-7% from 3-6%; reported revenue 5-8% from 4-7%; adjusted operating margin 50-100 bps expansion YoY (unchanged); adjusted EPS comparable to reported revenue growth (unchanged); free cash…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HAEHaemonetics CorporationFollow HAE — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 5.4B
P/E TTM: 57.3
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	FY27 organic revenue raised to 4-7% from 3-6%; reported revenue 5-8% from 4-7%; adjusted operating margin 50-100 bps expansion YoY (unchanged); adjusted EPS comparable to reported revenue growth (unchanged); free cash flow conversion ~80% (unchanged) · full year
7 May 26	Raised	Fiscal 2027 guidance provided; momentum for fiscal 2027 and beyond · full year
5 Feb 26	Raised	Organic ex-CSL revenue growth raised to 8-10% from 7-10%; adjusted operating margin guidance raised. · full year
6 Nov 25	Raised	Total company organic revenue guidance raised to (1)-2% from previous; organic ex-CSL raised to 7-10%. · full year
7 Aug 25	Reaffirmed	FY26: total revenue -3 to -6% reported; organic -2 to +1%; organic ex-CSL +6 to +9%; adj. op margin 26-27%; adj. EPS $4.70-5.00; FCF $160-200M · full year

Haemonetics Corporation — questions

What guidance did Haemonetics Corporation give?: On 2026-08-06: "FY27 organic revenue raised to 4-7% from 3-6%; reported revenue 5-8% from 4-7%; adjusted operating margin 50-100 bps expansion YoY (unchanged); adjusted EPS comparable to reported revenue growth (unchanged); free cash flow conversion ~80% (unchanged)"
When does Haemonetics Corporation report earnings?: Haemonetics Corporation's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Haemonetics Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.